Oppenheimer Holdings Inc. reissued their outperform rating on shares of Kura Oncology Inc (NASDAQ:KURA) in a research note published on Friday. The brokerage currently has a $16.00 target price on the stock, down from their prior target price of $18.00.
KURA has been the topic of several other reports. Zacks Investment Research lowered Kura Oncology from a buy rating to a sell rating in a research report on Saturday, February 11th. Cann reissued an outperform rating and issued a $18.00 price objective on shares of Kura Oncology in a research report on Monday, March 6th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $13.55.
Kura Oncology (NASDAQ:KURA) traded down 1.13% during mid-day trading on Friday, reaching $8.75. The company’s stock had a trading volume of 16,844 shares. The stock’s 50-day moving average is $7.52 and its 200-day moving average is $6.19. The firm’s market capitalization is $166.64 million. Kura Oncology has a 12 month low of $2.50 and a 12 month high of $10.47.
Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Tuesday, March 14th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.03. On average, equities analysts anticipate that Kura Oncology will post ($2.01) EPS for the current year.
Your IP Address:
Hedge funds have recently made changes to their positions in the company. Partner Investment Management L.P. raised its stake in shares of Kura Oncology by 2.7% in the third quarter. Partner Investment Management L.P. now owns 23,646 shares of the company’s stock worth $148,000 after buying an additional 623 shares during the last quarter. First Republic Investment Management Inc. acquired a new stake in shares of Kura Oncology during the fourth quarter worth about $174,000. Renaissance Technologies LLC raised its stake in shares of Kura Oncology by 25.4% in the fourth quarter. Renaissance Technologies LLC now owns 30,600 shares of the company’s stock worth $181,000 after buying an additional 6,200 shares during the last quarter. Finally, Pillar Pacific Capital Management LLC acquired a new stake in shares of Kura Oncology during the third quarter worth about $191,000. 45.73% of the stock is currently owned by institutional investors and hedge funds.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.